Category Archives: Biotechnology

WASHINGTON--(BUSINESS WIRE)-- The Biotechnology Innovation Organization (BIO) today announced education program session titles and speakers for the 2017 BIO World Congress on Industrial Biotechnology. The education program features seven diverse content tracks with speakers from around the world over three days of the conference. The worlds largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrs de Montral in Montral, Qubec, Canada. Brent Erickson, executive vice president of BIOs Industrial & Environmental Section, stated, BIOs 2017 World Congress will feature the most diverse group of speakers and presenters in the conferences history, with scientists and executives from start-up companies, investors from the finance sector, consumer product manufacturers and government officials from across Canada, Europe, the United States and Asia. The education program and partnering system provide a unique forum for conference attendees to share the latest advances in renewable chemicals, synthetic biology, enzymes, food ingredients, fragrances, flavors, cosmetics, biofuels and biorefineries, agricultural crops and biobased materials. Sessions featuring Renewable Chemicals and Biobased Materials include: A Revolution in Biobased Products and Packaging Wed. July 26, 11:45 am Renewable Chemicals and Thermoplastics for Performance Materials Mon. July 24, 10:30 AM Scaling Novel and Innovative Processes … Continue reading →

NEW YORK, NY--(Marketwired - April 19, 2017) - Planda Biotechnology (PLPL) recently presented investors with its outlook for 2017 and a number of milestones that the company plans to accomplish in 2017. Planda's plans are certainly aggressive and representative of the new Chief Operating Officer (COO) -- someone we feel is ideally suited to move the company forward. It didn't take long at all for the new COO, Callum Cottrell-Duffield, to put his stamp on the company's future. Three weeks ago Planda named Callum Cottrell-Duffield as its new COO, a role that will have him running the day-to-day operations of the company. In the time since being named COO, he has put together a plan to not only get Planda back on track, but to also move it aggressively into the future. With Planda shifting from purely a research and development biotechnology company to a company that is more focused on operations and sales, Callum Cottrell-Duffield is the ideal person to run Planda's day-to-day activity. After all, he has been there from the beginning where he helped to prepare the company's 8,000-acre tea estate to grow, harvest and produce Planda's signature product, the highly bioavailable Phytofare Catechin Complex. Last year … Continue reading →

Wall Street research analysts offer views on future stock movement ofPuma Biotechnology Inc (NYSE:PBYI). These opinions are based on extensive research and broad knowledge of the company. Analysts polled by Thomson Reuters have set a consensus target price of $68.67 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. Analysts and investors may use different metrics in order to calculate a price target projection. A very common metric used is the price to earnins ratio of a company. This calculation comes from dividing the current share price by the projected earnings per share. At the time of writing, Puma Biotechnology Inc (NYSE:PBYI) has a P/E Ratio of N/A. Investors may also examine a companys PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. A company with a PEG Ratio below one may be seen as undervalued while a PEG Ratio above one may signal that the company is overvalued. A PEG Ratio close to one may be considered to be fair value. Currently, the stock has a … Continue reading →

Photo: Jamie McCarthy/Getty Images for Glamour Two years after the $9 billion start-up unicorn Theranos crumbled, Silicon Valley still appears to be struggling to learn its lesson when it comes to health and medical start-ups. Improbable-sounding companies continue to turn up with tens of millions of dollars in funding, no published research to back them up, and nothing but criticism from scientists. Last week, BuzzFeed News examined a new set of start-ups promising to detect cancer early via a simple blood test Freenome, Grail, and Guardant and found them on paths dangerously similar to the one Theranos was on just a few years ago. A year ago, Freenome promised to publish about its product in a scientific journal very soon to Fast Company, and still hasnt. Cancer researchers told BuzzFeed very plainly that such a simple test would be miraculous but seemed improbably advanced beyond our current technology, which was also the case with Theranoss miniature blood tests and Freenome made its lofty promises only months after Theranos started to fall apart. Like a Kickstarter project well over its anticipated delivery date, one begins to wonder if it was all fake. Silicon Valley has a kind of blind spot when … Continue reading →

Technical traders have a large inventory of technical indicators they may use when doing technical stock analysis. After a recent look, the 14-day ATR for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is resting at 0.47. First developed by J. Welles Wilder, the ATR may help traders in determining if there is heightened interest in a trend, or if extreme levels may be indicating a reversal. Simply put, the ATR determines the volatility of a security over a given period of time, or the tendency of the security to move one direction or another. Some investors may find the Williams Percent Range or Williams %R as a helpful technical indicator. Presently, Powershares Dynamic Biotechnology and Genome Portfolio (PBE)s Williams Percent Range or 14 day Williams %R is resting at -43.44. Values can range from 0 to -100. A reading between -80 to -100 may be typically viewed as strong oversold territory. A value between 0 to -20 would represent a strong overbought condition. As a momentum indicator, the Williams R% may be used with other technicals to help define a specific trend. Investors may use multiple technical indicators to help spot trends and buy/sell signals. Presently, Powershares Dynamic Biotechnology and … Continue reading →

LOS ANGELES, Calif.--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has scheduled the New Drug Application (NDA) for neratinib for discussion by the Oncologic Drugs Advisory Committee (ODAC) on May 24, 2017. Neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen. ODAC is an independent panel of experts that evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of cancer and makes appropriate recommendations to the FDA. Although the FDA will consider the recommendation of the panel, the final decision regarding the approval of the product is made by the FDA solely, and the recommendations by the panel are non-binding. Puma Biotechnology announced on September 20, 2016 that the FDA had accepted for filing the NDA for neratinib. The NDA for neratinib is based on results from both the Phase III ExteNET trial in extended adjuvant early stage HER2-positive breast cancer and the Phase II CONTROL trial in extended adjuvant early stage HER2-positive breast cancer. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical … Continue reading →

M3 Biotechnology Raises $1.4M in Second Funding Round FinSMEs (blog) M3 Biotechnology, a Seattle, WA-based therapeutics company, raised $1.4m in a second funding round. Backers included Dolby Family Ventures and the Alzheimer's Drug Discovery Foundation (ADDF). The company, which has raised $14M in total financing ... See the article here: M3 Biotechnology Raises $1.4M in Second Funding Round - FinSMEs (blog) … Continue reading →

Market.Biz: Research Report on Biotechnology Separation Systems Industry 2016 provides the analytical view of the Biotechnology Separation Systems industry globally, focusing on main regions like North America, Europe, and Asia. Amongst these continental Biotechnology Separation Systems market, the report focuses on Biotechnology Separation Systems market by countries like United States Biotechnology Separation Systems market, Germany Biotechnology Separation Systems market, Japan and China Biotechnology Separation Systems market. In the first part, the Biotechnology Separation Systems market report lists the fundamental details of Biotechnology Separation Systems industry elaborating Biotechnology Separation Systems definition, classification, wide range of applications and Biotechnology Separation Systems industry frame structure. The report further includes Biotechnology Separation Systems industry policies and plans, Biotechnology Separation Systems product specification, cost structures and manufacturing process on Biotechnology Separation Systems market scenario. The report then studies the global Biotechnology Separation Systems market in terms of growth rate, Biotechnology Separation Systems consumption volume, Biotechnology Separation Systems production capacity, supply and demand ratio etc. Do Inquiry Before Purchasing Report Here: https://market.biz/report/global-biotechnology-separation-systems-market-2017-9dimen/70115/#inquiry 1) Report on Biotechnology Separation Systems industry covers growth rate (forecast). 2) Worldwide Biotechnology Separation Systems market 2017 estimated at USD XXXX in 2016. 3) Global Biotechnology Separation Systems industry 2017 projected to reach … Continue reading →

Post Analyst Puma Biotechnology, Inc. (NASDAQ:PBYI) held by 19 SEC 13F Filers Post Analyst Puma Biotechnology, Inc. (NASDAQ:PBYI) reached 80.6% versus a 1-year low price of $19.74. The stock was last seen -0.14% lower, reaching at $35.65 on Apr. 13, 2017. At recent session, the prices were hovering between $35.4 and $36.75. This company ... Research Brokerage Views on Puma Biotechnology, Inc. (NYSE:PBYI) DSP Group, Inc. (NASDAQ:DSPG)Sherwood Daily all 2 news articles » Read the rest here: Puma Biotechnology, Inc. (NASDAQ:PBYI) held by 19 SEC 13F Filers - Post Analyst … Continue reading →

iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. Markets Daily iShares NASDAQ Biotechnology Index logo Vetr upgraded shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) from a hold rating to a buy rating in a research note released on Wednesday. They currently have $301.57 target price on the stock. and more » View original post here: iShares NASDAQ Biotechnology Index (IBB) Upgraded at Vetr Inc. - Markets Daily … Continue reading →